Skip to main content
Clinical Trials/NCT04295369
NCT04295369UnknownNot Applicable

Effect of a Culturally Adapted Self-help Smartphone-based Lifestyle Intervention in Improving Psychological Well-being: A Pilot Randomized Controlled Trial

Chinese University of Hong Kong1 site in 1 country30 target enrollmentStarted: February 10, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
30
Locations
1
Primary Endpoint
Change in the Depression Anxiety Stress Scales-21

Study Overview

Brief Summary

This study will examine the effects of a smartphone-based lifestyle medicine (LM) for improving psychological well-being in Chinese population. Since a range of lifestyle factors are involved in the pathogenesis and progression of common mental disorders (e.g., depression and anxiety), modifying different lifestyle factors simultaneously may be effective to improve our psychological well-being. Chinese dietary recommendations will be integrated into the app to increase the acceptability towards mental health intervention. Through this study, we aim to promote evidence-based patient care and to improve help-seeking and access to evidence-based interventions for improving psychological well-being.

Detailed Description

This study will be a randomized controlled trial on the effects of a culturally adapted self-help smartphone-based lifestyle medicine for improving psychological well-being in Chinese population. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Around 30 eligible participants will be randomly assigned to either smartphone-based lifestyle medicine (LM group) or the waitlist control group (WL group) in a ratio of 1:1.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Hong Kong residents
  • Aged ≥ 18 years
  • Able to read Chinese and type in Chinese or English
  • Have an Internet-enabled mobile device (iOS or Android operating system)
  • Are willing to provide informed consent and comply with the trial protocol

Exclusion Criteria

  • Have a Patient Health Questionnaire (PHQ-9) score ≥ 10
  • Have a Generalized Anxiety Disorder 7-Item Scale (GAD-7) ≥ 8
  • Current involvement in psychotherapy or unstable medication for depression and/or anxiety
  • Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk)
  • Are having unsafe conditions and are not recommended for physical activity or a change in diet by physicians
  • Having major psychiatric, medical or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification

Outcomes

Primary Outcomes

Change in the Depression Anxiety Stress Scales-21

Time Frame: Immediately post-treatment and 1-month post treatment

DASS-21 is a 21-items scale, comprises of three sub-scales which measures the negative emotional states of depression, anxiety, and stress, over the past week. The DASS is based on a dimensional rather than a categorical conception of psychological disorder, thus it has no direct implications for the allocation of patients to discrete diagnostic categories. However, recommended cutoff scores for conventional severity labels (normal, moderate, severe) are given in the DASS Manual.

Secondary Outcomes

  • Change in the Health-Promoting Lifestyle Profile (HPLP II)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in the Short Form (Six-Dimension) Health Survey (SF-6D)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in The Insomnia Severity Index (ISI)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in the Sheehan Disability Scale (SDS)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in the Credibility-Expectancy Questionnaire (CEQ)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in the Food Frequency Questionnaires (FFQs)(Baseline, immediately post-treatment and 1-month post treatment)
  • Change in the International Physical Activities Questionnaire - Chinese version (IPAQ-C)(Baseline, immediately post-treatment and 1-month post treatment)
  • Self-developed survey(Baseline)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fiona YY Ho

Assistant Professor

Chinese University of Hong Kong

Study Sites (1)

Loading locations...

Similar Trials